ABSTRACT
Introduction Understanding the cellular immune response to SARS-CoV-2 is critical to vaccine development, epidemiological surveillance and control strategies. This systematic review critically evaluates and synthesises the relevant peer-reviewed and pre-print literature published in recent months.
Methods For this systematic review, independent keyword-structured literature searches were carried out in MEDLINE, Embase and COVID-19 Primer for studies published from 01/01/2020-26/06/2020. Papers were independently screened by two researchers, with arbitration of disagreements by a third researcher. Data were independently extracted into a pre-designed Excel template and studies critically appraised using a modified version of the MetaQAT tool, with resolution of disagreements by consensus. Findings were narratively synthesised.
Results 61 articles were included. Almost all studies used observational designs, were hospital-based, and the majority had important limitations. Symptomatic adult COVID-19 cases consistently show peripheral T cell lymphopenia, which positively correlates with increased disease severity, duration of RNA positivity, and non-survival; while asymptomatic and paediatric cases display preserved counts. People with severe or critical disease generally develop more robust, virus-specific T cell responses. T cell memory and effector function has been demonstrated against multiple viral epitopes, and, cross-reactive T cell responses have been demonstrated in unexposed and uninfected adults, but the significance for protection and susceptibility, respectively, remains unclear.
Interpretation A complex pattern of T cell response to SARS-CoV-2 infection has been demonstrated, but inferences regarding population level immunity are hampered by significant methodological limitations and heterogeneity between studies. In contrast to antibody responses, population-level surveillance of the cellular response is unlikely to be feasible in the near term. Focused evaluation in specific sub-groups, including vaccine recipients, should be prioritised.
Competing Interest Statement
JM is chief scientific officer, shareholder and scientific founder of Leucid Bio, a spinout company focused on development of cellular therapeutic agents. The authors report no other competing financial interests or conflicts of interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020192528
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. MCIvS is funded by a NIHR Doctoral Fellowship (Ref NIHR300156). SAI is supported by a Wellcome Trust Clinical Research Training Fellowship (Ref No 215654/Z/19/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Denotes corresponding author.
Data Availability
This was a systematic review based on analysis of openly published secondary data.
LIST OF ABBREVIATIONS
- ARDS
- Acute respiratory distress syndrome
- COVID-19
- Coronavirus disease (2019)
- CRS
- Cytokine release syndrome
- ELISpot
- Enzyme-linked immune absorbent spot (assay)
- HCoV
- Human Coronavirus (HKU1, 229E, OC43, NL63)
- IFN-γ
- Interferon gamma
- M
- Membrane (protein)
- MEDLINE
- Medical Literature Analysis and Retrieval System Online
- MERS
- Middle East Respiratory Syndrome
- MetaQAT
- Meta Quality Appraisal Tool
- NP
- Nucleocapsid protein
- NSP7; NSP13
- Non-structural protein 7; non-structural protein 13
- PBMC
- Peripheral blood mononuclear cells
- PCR; RT-PCR
- Polymerase chain reaction; reverse transcription polymerase chain reaction
- PRISMA
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- SARS-CoV-1
- Severe Acute Respiratory Syndrome Coronavirus-1
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus-2
- RBD
- Receptor binding domain
- RNA
- Ribonucleic acid
- TEMRA
- T effector memory cells re-expressing CD45RA
- TFH; cTFH
- T follicular helper cells; circulating T follicular helper cells
- Th
- T helper cells
- WHO
- World Health Organization
